Rosetta Genomics Ltd. (ROSG) Posts Q4, FY2010 Results
Rosetta Genomics Ltd., a leading developer of microRNA-based molecular diagnostics, today posted its financial results for the fourth quarter and 12 months ended December 31, 2010. "2010 was a challenging but rewarding year for Rosetta Genomics, marked by achievements in a number of important areas. We streamlined our operations and cost structure, expanded our distribution into Greece, advanced miRview mets to commercial launch, fortified our patent portfolio and, importantly, regained U.S. rights to our first three commercial microRNA diagnostic tests. Moreover, we significantly expanded our scientific and clinical body of knowledge with multiple journal publications of data demonstrating the role…